CI Global Health Sciences Corporate Class

Series F USD
 

Fund overview

This fund invests primarily in equity and equity-related securities of companies around the world that specialize in the health care or medical industry.

Fund details

description of elementelement value
Inception date August 2000
CAD Total net assets ($CAD)
As at 2026-07-31
$256.8 million
NAVPS
As at 2026-08-13
$29.6902
MER (%)
As at 2026-03-31
1.24
Management fee (%) 0.90
Asset class Sector Equity
Currency USD
Minimum investment $500 initial/$25 additional
Distribution frequency Quarterly
Last distribution $0.5033

Risk rating1

  • Low
  • Low to medium
  • Medium
  • Medium to high
  • High

FUND CODES

F 324
A ISC 301
DSC SO* 401
LL SO 1401
P 90324
*No new purchases directly into switch only funds.

Performance2 As at 2026-07-31

Growth of $10,000 (Since inception date)

growth of 10k graph

Calendar year performance

annual performance graph

average annual compound returns

YTD 1 Mo 3 Mo 6 Mo 1 Y 3 Y 5 Y 10 Y Inception*
2.99% 2.38% 14.36% 3.09% 22.14% 3.21% 0.12% 3.12% 7.09%
*Since inception date

Distribution history3

Payable date Total
2022-03-25 0.5033
2021-03-26 0.1714
2020-12-18 0.2724
2020-09-25 0.2584
2020-06-26 0.1886
Payable date Total
2020-03-20 0.4395
2019-12-13 0.2744
2019-09-27 0.3063
2019-06-21 0.2883
2019-03-22 0.4530

Management team

First we'll display the Team Company and then the Team members
Peter Hofstra

CI Global Health Sciences Corporate Class

Series F USD
 
Portfolio allocations4 As at 2026-07-31
Asset allocation (%)
  • US Equity 78.65
  • International Equity 17.37
  • Canadian Corporate Bonds 2.58
  • Cash and Equivalents 1.40
Sector allocation (%)
  • Healthcare 92.18
  • Exchange Traded Fund 3.42
  • Fixed Income 2.58
  • Cash and Cash Equivalent 1.40
  • Other 0.42
Geographic allocation(%)
  • United States 78.24
  • Switzerland 7.44
  • United Kingdom 6.09
  • Canada 3.94
  • Netherlands 3.86
  • Other 0.42
  • Denmark 0.01
Top holdings6
Sector (%)
1. Eli Lilly and Co Drugs 9.36%
2. UnitedHealth Group Inc Healthcare Services 7.81%
3. Johnson & Johnson Drugs 7.75%
4. Thermo Fisher Scientific Inc Healthcare Equipment 6.20%
5. AstraZeneca PLC Drugs 6.09%
6. Merck & Co Inc Drugs 6.06%
7. AbbVie Inc Drugs 5.47%
8. Stryker Corp Healthcare Equipment 5.01%
9. Danaher Corp Healthcare Equipment 4.88%
10. DexCom Inc Healthcare Equipment 4.53%
11. IQVIA Holdings Inc Drugs 4.50%
12. Abbott Laboratories Healthcare Equipment 4.06%
13. argenx SE Drugs 3.86%
14. Novartis AG Cl N Drugs 3.52%
15. SPDR S&P Biotech ETF (XBI) Exchange Traded Fund 3.42%
Over 35,000 financial advisors have chosen CI Global Asset Management as a partner. We believe that Canadians have the best opportunity for investments success by using the services of a professional financial advisor. Learn more at ci.com.